 | |
| Clinical data | |
|---|---|
| Trade names | Visudyne, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607060 |
| License data | |
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C41H42N4O8 |
| Molar mass | 718.807 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Verteporfin, sold under the trade name Visudyne among others, is a medication used to treat the wet form of age-related macular degeneration and choroidal neovascularisation due to severe short-sightedness.[1] It is given by injection into a vein followed by the use of a laser to activate it.[1][3] Both eyes may be treated following a single dose.[1]
Common side effects include pain at the site of injection and vision changes.[2] Other side effects may include shortness of breath, headache, tiredness, and fever.[3] It should not be used in those with acute porphyria.[3] It is a benzoporphyrin derivative.[2] Once activated it creates oxygen molecules in the area which block off excessive blood vessels.[1]
Verteporfin was approved for medical use in the Europe and the United States in 2000.[2][1] In the United Kingdom a vial of 15 mg costs the NHS about £850 as of 2021.[3] In the United States this amount costs about 1,800 USD.[4]
References edit
- ^ a b c d e f "Visudyne". Archived from the original on 27 May 2021. Retrieved 13 September 2021.
- ^ a b c d "Verteporfin Monograph for Professionals". Drugs.com. Archived from the original on 22 May 2021. Retrieved 13 September 2021. Cite error: The named reference "AHFS2021" was defined multiple times with different content (see the help page).
- ^ a b c d e BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1256. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ "Visudyne Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 13 September 2021.